Sialidase Fusion Protein as Inhibitor of Infection by Influenza Virus
Malakhov et al. reported that sialidase fusion protein could be used as a novel broad-spectrum inhibitor of influenza virus infection (2) . They showed a 90% effective concentration (nM) of 6.5 Ϯ 86.8 in Table 1 as the concentration of DAS181 that gave rise to 90% cell protection from influenza virus A/Victoria/504/2000 infection (2) . However, it is extremely unusual for three positive numbers with an average of 6.5 to have a standard deviation of 86.8, suggesting that the standard deviation may be a typographical error. The authors should explain this oddity.
Malakhov et al. mentioned in the abstract of their paper that "mouse and ferret studies confirmed significant in vivo efficacy of the sialidase fusion in both prophylactic and treatment modes." In my opinion, the ferret studies presented in Table 6 of the paper do not really support that statement. Comparing the mean values of virus titers (log 10 50% tissue culture infective dose/ml) between vehicle-treated ferrets and sialidase fusion protein-treated ferrets on day 1 (4.4 versus 2.4), day 2 (4.7 versus 4.6), day 3 (2.7 versus 3.9), day 4 (3.7 versus 3.4), and day 5 (negative value versus 2.6) postinfection, it is hard for readers to understand how Malakhov et al. could make the conclusion that differences between these two groups are significant. Additionally, Malakhov et al. omitted the chapter title, page numbers, and names of the editors for their reference 12, which makes it difficult for readers to find the cited reference. Therefore, I list here the complete information for that reference (1).
